Gastroesophageal Cancer – Landscape & Forecast – Disease Landscape & Forecast
The gastroesophageal cancer therapy market (including gastric, gastroesophageal junction, and esophageal cancer) is rapidly evolving and experiencing substantial growth, largely driven by the increasing uptake of immune checkpoint inhibitors. The label expansions of Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) and Keytruda (Merck & Co.), as well as the expected approvals of other immune checkpoint inhibitors, will continue to reshape the HER2-negative gastroesophageal cancer therapy market. Immune checkpoint inhibitors in combination with HER2-targeted agents and chemotherapy, as well as the anti-HER2 antibody-drug conjugate Enhertu (Daiichi Sankyo / AstraZeneca), are poised to expand treatment options for HER2-positive disease. Other therapies are targeting niche biomarkers (e.g., claudin18.2, FGFR2b) and will provide novel treatments for these patient subpopulations.
Questions answered
- How is gastroesophageal cancer segmented by subpopulation, and how will the recent drug approvals and label expansions to specific subpopulations impact the market?
- What are the key current therapies for gastroesophageal cancer, and how are they positioned in the treatment algorithm?
- Which emerging therapies are the most promising, and how will they shape the future of the gastroesophageal cancer therapy market?
- What are the drivers of and constraints in the gastroesophageal cancer therapy market, and how will the market evolve over the forecast period?
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Gastroesophageal Cancer - Landscape & Forecast - Disease Landscape & Forecast
- Key Findings
- Key Updates
- Market Outlook
- Key findings
- Major-market share of drug classes in gastroesophageal cancer: 2022
- Major-market share of drug classes in gastroesophageal cancer: 2032
- Major-market sales of key therapies for gastroesophageal cancer: 2022-2032
- Drug-treatable population share and major-market sales share in gastroesophageal cancer: 2022
- Drug-treatable population share and major-market sales share in gastroesophageal cancer: 2032
- Population positioning of therapies in gastric or GEJ adenocarcinoma: United States and Europe
- Population positioning of therapies in gastric or GEJ adenocarcinoma: Japan
- Population positioning of therapies in esophageal cancer: United States and Europe
- Population positioning of therapies in esophageal cancer: Japan
- Gastroesophageal cancer SWOT analysis
- Market drivers and constraints
- Segment-specific trends
- Key findings
- Forecast
- Etiology and Pathophysiology
- Disease overview
- Disease pathophysiology
- Anatomy of the stomach and the gastroesophageal junction
- Anatomy of the stomach and the gastroesophageal junction
- Anatomy of the esophagus
- Anatomy of the esophagus
- Subtype classification and development of gastric and gastroesophageal junction adenocarcinoma
- Key stages in the development of intestinal and diffuse types of gastric andu00a0gastroesophageal junctionu00a0adenocarcinoma
- Subtype classification and development of esophageal cancer
- Key stages in the development of esophageal cancer
- Staging and classification
- AJCC / UICC TNM classification system for gastroesophageal cancer
- AJCC / UICC clinical staging classification system for gastroesophageal cancer
- AJCC / UICC pathological staging classification system for gastroesophageal cancer
- AJCC / UICC postneoadjuvant therapy staging classification system for gastroesophageal cancer
- Key pathways and drug targets
- Disease overview
- Epidemiology
- Current Treatment
- Key findings
- Treatment goals
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for gastroesophageal cancer
- Current treatments used for gastroesophageal cancer
- Market events impacting the use of key current therapies for gastroesophageal cancer
- Angiogenesis inhibitors
- HER2 inhibitors
- Immune checkpoint inhibitors
- Cytotoxic agents
- Medical practice
- Localized and resectable locally advanced gastroesophageal cancer
- Unresectable locally advanced gastroesophageal cancer
- First-line metastatic gastroesophageal cancer
- Second-line metastatic gastroesophageal cancer
- Third- and fourth-line metastatic gastroesophageal cancer
- Patient characteristics influencing drug selection in gastroesophageal cancer
- Region-specific treatment practices
- Key findings
- Unmet Need Overview
- Drug Pipeline
- Emerging Therapies
- Access and Reimbursement Overview
- Methodology
- Appendix
Khurram Nawaz, M.Sc., Senior Manager, Healthcare Research & Data Analytics, Oncology. Mr. Nawaz manages an international team of analysts who conduct market research and build oncology drug market forecasts. He provides deep expertise to internal and external partners, translating domain knowledge into actionable insights. He has over 13 years of experience in market forecasting and a keen interest in immuno-oncology, non-small cell lung cancer, and a wide range of other solid and hematological malignancies. Prior to joining the company, he contributed to the preclinical development of candidate drugs for schizophrenia and cognitive disorders at GSK. He received his master’s degree in biotechnology engineering from the University of Aix-Marseille in France.
Narendra Parihar, B.D.S., M.P.H., Senior Manager, Epidemiology. Dr Parihar is a team lead at Clarivate Epidemiology. He specializes in modelling and forecasting epidemiology patient populations across multiple indications. His primary areas of interest are cancer epidemiology, rare disease epidemiology, and targeted therapies in cancer. His qualifications include a master’s degree in public health with specialization in health policy, economics, and finance from Tata Institute of Social Sciences Mumbai, and a bachelor’s degree in dental surgery from the Rajasthan University of Health Sciences.